Miacalcin

Miacalcin is a brand name of calcitonin, approved by the FDA in the following formulation(s):

MIACALCIN (calcitonin salmon - injectable; injection)

• 
  Manufacturer: NOVARTIS
  
  Approval date: March 29, 1991
  
  Strength(s): 200 IU/ML ^[RLD]

MIACALCIN (calcitonin salmon - spray, metered; nasal)

• 
  Manufacturer: NOVARTIS
  
  Approval date: August 17, 1995
  
  Strength(s): 200 IU/SPRAY ^[RLD][AB]

Has a generic version of Miacalcin been approved?

A generic version of Miacalcin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Miacalcin and have been approved by the FDA:

CALCITONIN-SALMON (calcitonin salmon spray, metered; nasal)

• 
  Manufacturer: APOTEX INC
  
  Approval date: November 17, 2008
  
  Strength(s): 200 IU/SPRAY ^[AB]


• 
  Manufacturer: PAR PHARM
  
  Approval date: June 8, 2009
  
  Strength(s): 200 IU/SPRAY ^[AB]

Note: No generic formulation of the following product is available.

• calcitonin salmon - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Miacalcin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Galenic compositions comprising calcitonin and their use
  Patent 5,733,569
  Issued: March 31, 1998
  Inventor(s): Azria; Moise & Cavanak; Thomas
  Assignee(s): Novartis Corporation
  Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.
  
  Patent expiration dates:
  
  
  • March 31, 2015
    
    ✓ 
    Patent use: NASAL ADMINISTRATION
  
  



• 
  Galenic compositions comprising calcitonin and their use
  Patent 5,759,565
  Issued: June 2, 1998
  Inventor(s): Azria; Moise & Cavanak; Thomas
  Assignee(s): Novartis Corporation
  Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.
  
  Patent expiration dates:
  
  
  • March 31, 2015
    
  
  

See also...

• Miacalcin Consumer Information (Drugs.com)
• Miacalcin Consumer Information (Wolters Kluwer)
• Miacalcin Spray Consumer Information (Wolters Kluwer)
• Miacalcin Consumer Information (Cerner Multum)
• Miacalcin Injection Advanced Consumer Information (Micromedex)
• Miacalcin Nasal Advanced Consumer Information (Micromedex)
• Miacalcin Parenteral Advanced Consumer Information (Micromedex)
• Calcitonin Salmon Spray Consumer Information (Wolters Kluwer)
• Calcitonin-Salmon Consumer Information (Wolters Kluwer)
• Calcitonin injection Consumer Information (Cerner Multum)
• Calcitonin nasal Consumer Information (Cerner Multum)
• Calcitonin (salmon) Nasal Advanced Consumer Information (Micromedex)
• Calcitonin Injection Advanced Consumer Information (Micromedex)
• Calcitonin Nasal Advanced Consumer Information (Micromedex)
• Calcitonin Parenteral Advanced Consumer Information (Micromedex)
• Calcitonin AHFS DI Monographs (ASHP)